Insulin Pump Therapy and Adverse Skin Reactions With Focus on Allergic Contact Dermatitis in Individuals Living With Diabetes Mellitus: A Systematic Review and Clinical-Based Update
Authors' conclusion
The review and our findings indicate that there is not sufficient focus on contact allergy in the primary toxicological evaluations of substances used also for insulin pump therapy products and that possible adverse skin reactions are not correctly followed up in the clinical setting.
Study context
- Population
- Children and adults with DM (mainly T1D) using CSII, full-text studies reporting dermatitis; plus referrals to the Department of Occupational and Environmental Dermatology, Malmö, Sweden21 studies
- Outcome
- Dermatitis including allergic contact dermatitis (ACD) related to insulin pumps/infusion sets
Methodological detailsclinical-based update, Newcastle-Ottawa Scale quality assessment, PubMed and EMBASE searched, 2020 to 2023
- Clinical-based update
- Newcastle-Ottawa Scale quality assessment
- PubMed and EMBASE searched, 2020 to 2023
Pooled result
As reported in the abstract
Dermatitis including ACD with CSII
- Studies fulfilling inclusion criteria, of 391 screened abstracts
- 21
- Studies on children only
- 7
- Studies on adults
- 4
- Studies on both children and adults
- 9
- Allergic contact dermatitis (ACD) among those referred to a university hospital for skin reactions possibly related to insulin pumps
- Up to 60%
Original publication
Insulin Pump Therapy and Adverse Skin Reactions With Focus on Allergic Contact Dermatitis in Individuals Living With Diabetes Mellitus: A Systematic Review and Clinical-Based Update. J Diabetes Sci Technol. Published 10 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →